Delcath Systems Management
Management criteria checks 4/4
Delcath Systems' CEO is Gerard Michel, appointed in Oct 2020, has a tenure of 5.33 years. total yearly compensation is $2.16M, comprised of 26% salary and 74% bonuses, including company stock and options. directly owns 0.95% of the company’s shares, worth $3.24M. The average tenure of the management team and the board of directors is 2.7 years and 5.8 years respectively.
Key information
Gerard Michel
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 25.99% |
| CEO tenure | 5.3yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.7yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 28% Share Price Plunge
Nov 21
Delcath: Temporary Headwinds Are No Cause For Concern
Nov 06The Delcath Systems, Inc. (NASDAQ:DCTH) Analysts Have Been Trimming Their Sales Forecasts
Oct 28Delcath Systems, Inc. Just Recorded A 200% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 09Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 29% Share Price Plunge
Jul 12Delcath Systems (NASDAQ:DCTH) Is In A Strong Position To Grow Its Business
Jun 18Delcath Systems, Inc.'s (NASDAQ:DCTH) 52% Jump Shows Its Popularity With Investors
May 22Delcath Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 11
HEPZATO Launch And European Expansion Will Expand Treatment Access
Expansion in U.S. treatment centers and commercial teams is expected to drive significant revenue growth and improve operational efficiencies.With A 27% Price Drop For Delcath Systems, Inc. (NASDAQ:DCTH) You'll Still Get What You Pay For
Mar 11Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 31% Share Price Bounce
Jan 18Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?
Dec 19Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Nov 18Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Nov 01Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors
Sep 10Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?
Aug 27Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aug 07Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?
Jan 15Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?
Oct 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$1m |
| Jun 30 2025 | n/a | n/a | US$2m |
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$2m | US$561k | -US$26m |
| Sep 30 2024 | n/a | n/a | -US$34m |
| Jun 30 2024 | n/a | n/a | -US$56m |
| Mar 31 2024 | n/a | n/a | -US$50m |
| Dec 31 2023 | US$3m | US$538k | -US$48m |
| Sep 30 2023 | n/a | n/a | -US$45m |
| Jun 30 2023 | n/a | n/a | -US$34m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$1m | US$521k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$2m | US$475k | -US$26m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$25m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$6m | US$113k | -US$24m |
Compensation vs Market: Gerard's total compensation ($USD2.16M) is about average for companies of similar size in the US market ($USD2.25M).
Compensation vs Earnings: Gerard's compensation has been consistent with company performance over the past year.
CEO
Gerard Michel (62 yo)
Mr. Gerard J. Michel, MS, MBA, is an Independent Director of Beta Bionics, Inc. from March 26, 2025. Mr. Michel serves as Chief Executive Officer and Director at Delcath Systems Inc since October 1, 2020....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$2.16m | 0.95% $ 3.2m | |
| Chief Operating Officer | 1.9yrs | US$1.02m | 0.014% $ 46.4k | |
| Chief Medical Officer | 2.7yrs | US$1.49m | 0.49% $ 1.7m | |
| Chief Financial Officer | 2.7yrs | no data | 0.20% $ 687.6k | |
| General Counsel | 4.1yrs | no data | 0.24% $ 817.5k | |
| Senior Vice President of Clinical Operations & Medical Affairs | 5.1yrs | US$737.50k | no data | |
| Senior Vice President of Interventional Oncology | less than a year | no data | no data |
Experienced Management: DCTH's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$2.16m | 0.95% $ 3.2m | |
| Independent Director | 6yrs | US$205.67k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$204.13k | 0.53% $ 1.8m | |
| Independent Chairman | 6.6yrs | US$229.17k | 0.043% $ 146.1k | |
| Independent Director | 5.8yrs | US$192.20k | 0.38% $ 1.3m | |
| Director | 1.8yrs | US$176.25k | 0% $ 0 |
Experienced Board: DCTH's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/22 05:21 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Delcath Systems, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |
| John Newman | Canaccord Genuity |